Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate CNS Prophylaxis in Diffuse Large B-Cell Lymphoma
NCT02777736Phase 3Unknown
- Sponsor
- Kooperativní lymfomová skupina
- Start
- Jul 2015
- Primary completion
- Dec 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methotrexate in diffuse large B-cell lymphoma (DLBCL) (3 arms), sponsored by Kooperativní lymfomová skupina. Primary endpoint: Cumulative incidence of CNS relapse at 1 year. Status: unknown.
02
Drugs
methotrexate
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02777736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02777736.